BILATERAL CHOROIDAL DETACHMENTS FOLLOWING NOVEL CHIMERIC ANTIGEN RECEPTOR T-CELL IMMUNOTHERAPY REGIMEN.

BACKGROUND/PURPOSE: The aim of this study was to describe a vision-threatening adverse event of a novel chimeric antigen receptor T-cell immunotherapy for metastatic prostate cancer.

METHODS

This was an observational case report.

RESULTS

A 77-year-old male patient with a history of metastatic prostate cancer and pulmonary embolism enrolled in a clinical trial investigating the use of chimeric antigen receptor T-cell immunotherapy for treatment of metastatic prostate cancer presented with a subjective left temporal visual disturbance. The patient was found to have bilateral extensive choroidal detachments on examination. Optical coherence tomography macula demonstrated no intraretinal fluid or supraretinal fluid in both eyes. B-scan of both eyes redemonstrated choroidal detachments in both eyes and no retinal detachment in either eye. The patient was initiated on a topical and systemic steroid regimen and experienced symptomatic and clinical improvement.

CONCLUSION

The authors exhibit a case of bilateral choroidal detachments secondary to systemic reaction to a novel immunotherapy for metastatic cancer successfully treated with systemic and topical steroids. A close follow-up may be required for patients receiving similar novel immunotherapeutic regimens.